Patient Pathway Pharmacist - Optimal Drug-related Care
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03695081|
Recruitment Status : Recruiting
First Posted : October 3, 2018
Last Update Posted : April 4, 2019
|Condition or disease||Intervention/treatment||Phase|
|Hip Fractures Aging Patient Fall||Procedure: Patient Pathway Pharmacist intervention||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||
An intervention group is compared to a cross-sectional retrospective group.
A group of 60 patients with hip fracture will get an intervention by a clinical pharmacist who performs medication reconciliation and medication review during hospitalisation, they will receive a discharge summary where the medication part is optimised. After six weeks the patients will be get a follow-up with a second medication reconciliation and - review. This group will be compared with the last 50 patients with hip fracture who did not get the intervention.
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Patient Pathway Pharmacist: Drug Optimisation for Hip Fracture Patients - Facilitating a Safe Patient Handover: a Descriptive Study|
|Actual Study Start Date :||September 3, 2018|
|Estimated Primary Completion Date :||April 10, 2019|
|Estimated Study Completion Date :||August 30, 2019|
Experimental: Patient Pathway Pharmacist intervention
Procedure: Patient Pathway Pharmacist intervention
No Intervention: No intervention
Business as usual. The Patient Pathway Pharmacist is not involved and the nurses and physicians are responsible for medicine reconciliation, -review and section in the discharge summary.
- Discharge summary score [ Time Frame: At discharge (estimated five days after fracture/inclusion) ]In the discharge summary, the section describing drugs is scored in accordance with the national patient safety program
- Admission summary score [ Time Frame: At hospital admission (estimated to be within 24 hours after fracture) ]In the admission summary, the section describing drugs is scored. The score is adjusted from the discharge summary score to fit the admission note.
- Discharge summaries written in accordance with procedure [ Time Frame: At discharge (estimated five days after fracture/inclusion) ]In the discharge summary, the section describing drugs should be in accordance with procedure.
- Number of inappropriate drugs at discharge [ Time Frame: During hospitalisation, after surgery (estimated to be within five days after fracture/inclusion) ]After surgery the medication review may reduce the number of inappropriate drugs (on the STOPP-list).
- Readmission [ Time Frame: 30 days after discharge ]Patients who are readmitted to hospital is quantified
- Readmission [ Time Frame: 90 days after discharge ]Patients who are readmitted to hospital is quantified
- Death [ Time Frame: 30 days after discharge ]The number patients who dies is quantified
- Death [ Time Frame: 90 days after discharge ]The number of patients who dies is quantified
- Experience of current practice [ Time Frame: Prior to or during the early start of the intervention ]A questionnaire will be distributed to all health care professionals involved in the treatment of hip fracture patients
- Experience of patient pathway pharmacist [ Time Frame: Within three months after last included patient ]Focus groups or semi-structured interviews will be performed to assess the advantages and/or disadvantages of introducing a patient pathway pharmacist.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03695081
|Contact: Ben Tore Henriksen, MScfirstname.lastname@example.org|
|Contact: Maria Krogseth, PhD, MDemail@example.com|
|Vestfold Hospital Trust||Recruiting|
|Contact: Ben Tore Henriksen, MSc 004792499756 firstname.lastname@example.org|
|Contact: Maria Krogseth, MD, PhD 004797154442 email@example.com|